**SUMOylation Is Required for Optimal TRAF3 Signaling Capacity**

Sophia Miliara1,2, Kalliopi K. Gkouskou1,2, Tyson V. Sharp3, Aristides G. Eliopoulos1,2*

1 Molecular and Cellular Biology Laboratory, University of Crete School of Medicine, Heraklion, Greece, 2 Laboratory of Cancer Biology, Institute of Molecular Biology and Biotechnology, Foundation of Research and Technology Hellas, Heraklion, Greece, 3 Barts Cancer Institute, Queen Mary University of London, London, United Kingdom

**Abstract**

TNF receptor–associated factors (TRAFs) are multifunctional intracellular proteins which participate in the recruitment and activation of a plethora of protein kinases involved in immune and death receptor signaling. Among the seven known mammalian TRAFs, TRAF2, TRAF3 and TRAF6 have been extensively studied as their ablation severely impairs Toll-like and TNF family receptor signal transduction.

TRAF3 was originally identified as a molecule that binds the cytoplasmic domains of the TNF receptor family member CD40 and the oncogenic Epstein-Barr virus–encoded latent membrane protein 1 (LMP1) [1,2,3](reviewed in [4]). Subsequently, TRAF3 was shown to interact with the cytoplasmic tails of other TNF receptor family members, such as lymphotoxin-β-receptor (LTβR), OX40, CD27, CD30, Herpes virus entry mediator and receptor activator of NF-κB [5,6,7] and more recently to participate in Toll-like receptor signaling and to regulate the production of pro-inflammatory cytokines and type I interferons in response to a variety of pathogen-associated molecular patterns [8,9]. The participation of TRAF3 in signal transduction from diverse receptors reflects its major immunological role in host defense. Indeed, TRAF3 deficiency has been linked to lymphoid defects in the mouse and increased susceptibility to herpes simplex virus-1 (HSV-1)-induced encephalitis (HSE) in humans [10,11].

The impact of TRAF3 deregulation extends to the pathogenesis of malignancy. Inactivating mutations and loss of heterozygosity in the TRAF3 locus have been reported in a significant proportion of myeloma patients, suggesting that TRAF3 may function as a tumor suppressor [12,13]. In line with this notion, we and others have previously demonstrated that TRAF3 mediates the anti-proliferative effects of CD40 and LTβR in transformed cell lines [14,15] and that overexpressed TRAF3 inhibits the growth of carcinoma [14] and myeloma cells [13].

The role of TRAF3 in disease pathogenesis has partly been attributed to the engagement of the ‘alternative’ NF-κB pathway which involves the processing of p100 NF-κB2 to p52. In the absence of stimuli, TRAF3 is required for the formation of a cytoplasmic multi-protein complex containing TRAF2, NF-κB inducing kinase (NIK) and the cellular inhibitors of apoptosis (cIAP1/2). In this complex, the ubiquitin ligase activity of cIAPs is channeled towards NIK leading to its degradation [16,17]. Indeed, ablation of TRAF3 in the mouse or reduced TRAF3 levels in myeloma [12,13] and HSE patients [18] elevate NIK expression resulting in constitutive activation of the NF-κB2 pathway and accumulation of transcriptionally active p52. Deregulated NF-κB2 signaling accounts for the postnatal lethality associated with TRAF3 ablation [9].

Transient activation of p100 processing occurs in response to stimulation of TRAF3-interacting receptors, such as CD40 [19]. Ligation of CD40 in B cells results in rapid recruitment of a multi-protein complex containing TRAF2, TRAF3 and cIAP1/2 to the receptor. TRAF2 serves not only as adaptor protein but also as E3 ubiquitin ligase which functions together with the E2 ubiquitin-conjugating enzyme Ubc9 to catalyze the addition of lysine 63 (K63)-linked polyubiquitin chains to cIAP1/2. This, in turn, activates the ubiquitin ligase activity of cIAP1/2 toward TRAF3, catalyzing degradative K48–linked polyubiquitination. The ensuing degradation of TRAF3 results in NIK accumulation and activation through autophosphorylation [20]. Whereas TRAF3 negatively regulates alternative NF-κB2 signaling, it is...
required for the activation of IRF3 and the interferon (IFN) response, an effect attributed to K63 rather than K48-mediated Ub linkages [20].

The function of TRAFs in signal transduction exceeds, therefore, their role as molecular bridges between receptors and intracellular signaling components and includes active regulation of kinase activation through inducible ubiquitination. In this study using yeast two-hybrid cloning and co-immunoprecipitation assays we have identified Ubc9 as a novel TRAF3-interacting protein and demonstrated that TRAF3 is subject to an additional post-translational modification, namely SUMOylation. Furthermore, we show that the TRAF3:Ubc9 association affects the ability of TRAF3 to bind CD40 and signal on the non-canonical CD40-NF-kB2 axis.

Materials and Methods

Yeast two-hybrid screening

TRAF3 cloned into the GAL4 DNA-binding vector pAS1 was kindly provided by Professor George Mosialos (Aristotle University of Thessaloniki, Greece) and used as bait in a two-hybrid screening of HeLa cDNA library according to the Matchmaker Two-hybrid System Protocol (Clontech). Positive clones were recovered and sequenced. Interactions with Ubc9 were confirmed by transfection into the S. cerevisiae strain PJ69-4A and examination of growth in media lacking tryptophan and leucine (to select for the introduced plasmids) and also lacking either adenine (SD-leu-trp-ade) or containing X-gal (SD-leu-trp + 40 µg/ml X-gal) to assay galactosidase reporter gene expression.

Cell culture and transfections

EJ cells [28] were maintained in RPMI medium supplemented with 10% fetal bovine serum. 293T, a variant of the human embryonic kidney cell line 293 (ATCC, CRL3216) and HeLa cells stably expressing His-SUMO-1 and His-SUMO-2 (kindly provided by Prof. Ron Hay, University of Dundee, UK, [21]), were maintained in Dulbecco’s modified Eagle’s Medium (DMEM, Gibco) supplemented with 10% fetal calf serum in an atmosphere of 5% CO2, at 37°C. Transient transfections were performed using Lipofectamine (Invitrogen) according to the manufacturer’s protocol. Isolation of primary splenocytes was performed as previously described [19].

Plasmids

SUMO expression vectors were gift from Prof. Ron Hay. Human wild type Ubc9 was PCR amplified from a HeLa cDNA library using Expand High Fidelity PCR System (Roche, Germany) and the following primers: sense Bam-UBC-FORW 5'-CTTTGAACGGATCCGGGATCGCCCTC-3' and antisense Eco-UBC-REV 5'-CACAGGTAATTTATGAGGGCGCAAC-3' (MWG, Germany). The PCR amplification conditions were as follows: 94°C for 3 minutes followed by 29 cycles of 94°C for 30 seconds, 64°C for 40 seconds and 72°C for 45 seconds and a final extension step of 72°C for 5 minutes. A mutated Ubc9 carrying a substitution of Cys93 in the active site of the enzyme with Ala which is unable to form SUMO conjugates was provided by Dr Y.Y. Mo [22]. TRAF3 deletion mutants corresponding to aa 1-266 (Mutant 1), aa 1-376 (Mutant 2), aa 267-568 (mutant 3) and aa 346-568 (mutant 4) were generated by PCR using the following primers:

**Mutant 1F:** 5'-GGAAATTCAGTAAAAAGATGGACTCTCCTG-3',
**Mutant 1R:** 5'-CGACTCGAGTCACTCCTTCAGCAGG-3',
**Mutant 2F:** 5'-GGAAATTCAGTAAAAAGATGGACTCTCCTG-3',
**Mutant 2R:** 5'-ACTCGAGCAGGCCTCAGTTCCGAGC-3',
**Mutant 3F:** 5'-GGAAATTCAGCAGCTCGCCAAAGAAG-3',
**Mutant 3R:** 5'-CCTCGAGTGACGGATCAGG3',
**Mutant 4F:** 5'-GGAGGAATTCAGCAGCATGAAGAGCA-3',
**Mutant 4R:** 5'-GGAGGAATTCAGCAGCATGAAGAGCA-3',

![A.](image1.png)

**Figure 1.** TRAF3 interacts with Ubc9 in a yeast 2-hybrid assay. (A) S. cerevisiae strain PJ69-4A was transformed with plasmids expressing the GAL4 activation domain (AD) fused to Ubc9, the GAL4 binding domain (BD) fused to TRAF3 or with control empty vectors in all possible combinations. Cells were grown on standard medium (SD-leu-trp) in the presence of absence of X gal (SD-leu-trp + X gal), medium lacking adenine (SD-leu-trp-ade) to detect expression of the GAL-ADE2 reporter gene or medium lacking histidine (SD-leu-trp-his + 3-AT) to detect expression of the GAL-HIS3 reporter gene. (B) Quantification of galactosidase reporter activity in yeast transformed with the vectors described in (A). Results shown represent the mean values of galactosidase activity (±SD) relative to controls from 4 independent experiments.

doi:10.1371/journal.pone.0080470.g001
Mutant 4R: 5

PCR conditions were as follows: for mutant 1 and 4, 94°C for 2 minutes followed by 30 cycles of 94°C for 30 seconds, 61°C for 40 seconds and 72°C for 50 seconds and then extended by 72°C for 10 minutes; for mutants 2 and 3, 94°C for 2 minutes followed by 30 cycles of 94°C for 30 seconds, 61°C for 40 seconds and 72°C for 67 seconds and then extended by 72°C for 10 minutes. The TRAF3 mutants were cloned as EcoRI/XhoI fragments into a modified pcDNA3.1 (Invitrogen, CA, USA) vector containing a FLAG-tag and sequenced.

Preparation of protein extracts

Depending on the experimental setting, cells were lysed in different buffers. For native immunoprecipitations, cells were lysed in RIPA buffer (25 mM Tris-HCl pH 7.2, 50 mM NaCl, 0.5% NP40, 0.5% sodium deoxycholate) supplemented with 1% SDS and 25 mM N-Ethylmaleimide or iodoacetamide (Sigma). Alternatively, cells were lysed in Guanidinium-HCl to allow purification on Ni-NTA columns [21].

Co-Immunoprecipitation Studies

Cell lysates were cleared and incubated with anti-TRAF3 antibody (1 µg/mg lysate) and G-Sepharose Beads (20 µl) for 12 hours at 4°C on a rotor. The beads were washed extensively in Lysis Buffer A [23] and boiled with 30 µl Protein Loading Buffer [50 mM Tris pH 6.8, 4% SDS (w/v), 10% glycerol, 5% mercaptoethanol, 0.01% bromophenol blue (w/v)].

Western Analysis

Samples were analyzed by SDS-PAGE and transferred onto polyvinylidene difluoride membrane (0.45 µM; Millipore). The membranes were incubated with primary antibodies overnight at 4°C: TRAF3 (C20), TRAF2 (C20), IκBα (C21), RIP1 (C20) were purchased from Santa-Cruz Biotechnology, anti-myc tag 9E10, anti-FLAG M2 and α-actin antibodies were from Sigma and NF-κB2 antibody from Cell Signaling Technology. Anti-SUMO-1 and SUMO-2 antibodies were kindly provided by Professor Ron Hay, University of Dundee, UK. Following 1 h incubation with the appropriate secondary antibody, membranes were subjected to enhanced chemiluminescence analysis.

GST Pull-Down Assays

Isolation and purification of GST or GST-Ubc9 fusion protein were performed as previously described [23]. For pull-down assays, 500 µg total protein isolated from HEK293 cells was mixed with beads carrying GST or GST-Ubc9 and incubated for 2 h at
C. After three washes with PBS, proteins were solubilized in 1 x SDS protein sample buffer and separated in 8% SDS polyacrylamide gels.

Results

Isolation of Ubc9 as a TRAF3-interacting protein in yeast

To increase our understanding of the function of TRAF3, we performed yeast two-hybrid interaction assays to search for proteins that directly associate with TRAF3. An expression vector in which full-length TRAF3 was fused to the Gal4 DNA binding domain was used as bait to screen a HeLa cDNA library [24]. From approximately 10 million transformants, 10 independent positive clones were obtained. One of them encoded the full-length Ubc9, a protein associated with the process of SUMOylation.

To verify this interaction, S. cerevisiae strain PJ69-4A was transformed with plasmids expressing the GAL4 activation domain (AD) fused to Ubc9, the GAL4 binding domain (BD) fused to TRAF3 or with control empty vectors in all possible combinations. Cells were grown in standard medium (SD-leu-trp) in the presence or absence of iodocetamide (IDO) and immunoprecipitated (IP) with anti-TRAF3 C20 antibody. The SUMO-1 conjugates were detected by anti-SUMO-1 specific antibody. (D) SUMO-2/3 modification of TRAF3. Protein lysates were obtained from EJ cells in the presence of absence of IDA and TRAF3 immunoprecipitates (IP) were immunoblotted (IB) with an anti-SUMO-2/3 specific antibody.

doi:10.1371/journal.pone.0080470.g003

Figure 3. TRAF3 is post-translationally modified by SUMO. (A) HeLa cells stably expressing His-tagged SUMO-1 or SUMO-2 and parental cells were lysed in a protein-denaturing buffer and lysates were subjected to enrichment of SUMOylated proteins on nickel-nitrilotriacetic acid (Ni-NTA) columns. Eluates were immunoblotted with a TRAF3 polyclonal antibody. (B & C) SUMO-1 modification of TRAF3. Protein lysates were obtained from EJ bladder carcinoma, BJAB lymphoma and HeLa cervical carcinoma cells stably transfected with SUMO-1 (B) or mouse splenocytes (C) in the presence or absence of iodocetamide (IDO) and immunoprecipitated (IP) with anti-TRAF3 C20 antibody. The SUMO-1 conjugates were detected by anti-SUMO-1 specific antibody. (D) SUMO-2/3 modification of TRAF3. Protein lysates were obtained from EJ cells in the presence or absence of IDA and TRAF3 immunoprecipitates (IP) were immunoblotted (IB) with an anti-SUMO-2/3 specific antibody.

4°C. After three washes with PBS, proteins were solubilized in 1 x SDS protein sample buffer and separated in 8% SDS polyacrylamide gels.

TRAF3 associates with Ubc9 through its ring finger TRAF-N domain

To further validate the interaction between Ubc9 and TRAF3, a fusion of GST with Ubc9 was examined for its ability to interact with FLAG-tagged TRAF3 expressed in human embryonic kidney (HEK) 293 cells. As shown in Figure 2A, GST-Ubc9 strongly associated with TRAF3 whereas control GST did not. This interaction was further analyzed in mammalian cell co-immunoprecipitation assays. The full-length Ubc9 construct containing an N-terminal Myc epitope tag (myc-Ubc9) was transiently co-expressed in HEK 293 cells with FLAG-tagged TRAF3 or, as positive control, SMAD4 [25]. Cell lysates were immunoprecipitated using a monoclonal antibody against the FLAG epitope, and co-precipitating Ubc9 was detected by immunoblotting with (SD-leu-trp-ade) to detect expression of the GAL-ADE2 reporter gene or in medium lacking histidine (SD-leu-trp-his +3-AT) to detect expression of the GAL-HIS3 reporter gene. The growth patterns of the transformed cells and the expression levels of β-galactosidase activity confirmed that TRAF3 and Ubc9 interact in yeast (Fig. 1).
anti-Myc polyclonal antibody. As shown in Figure 2B, FLAG-TRAF3 interacted with Myc-Ubc9.

TRAF3 contains a N-terminal ring finger domain followed by several zinc fingers [3]. The C-terminal half of TRAF3 comprises the TRAF domain, which is conserved among all members of the TRAF family and can be further subdivided into the TRAF-N and TRAF-C regions [1]. To identify the TRAF3 domain which contributes to Ubc9 binding, various FLAG-tagged TRAF3 deletion mutants were generated (Fig. 2C) and assayed for association with GST-Ubc9. The results of the GST pull-down assays demonstrated that the TRAF-N domain of TRAF3 is predominantly responsible for binding to Ubc9 (Fig. 2D). However, binding was reduced compared to wild-type TRAF3 indicating conformational effects on effective interaction with Ubc9.

Ubc9 is required for SUMO modification of TRAF3

Similar to ubiquitin, SUMO is covalently conjugated to a substrate protein lysine through a reaction that utilizes an activating E1 enzyme, a conjugating E2 enzyme and an E3 ligase. Unlike the ubiquitination pathway where each E2 has a specific set of target proteins, SUMO conjugation is mediated exclusively by Ubc9. The association of TRAF3 with Ubc9 (Fig. 1 and 2) led us to postulate that TRAF3 is a SUMO substrate. In vertebrates, two SUMO protein subfamilies, SUMO-1 and SUMO-2/3 have mostly been studied. SUMO-2 and SUMO-3 are commonly referred to as SUMO-2/3 due to 98% sequence similarity and the lack, to date, of distinguishable functional differences.

HeLa cells stably expressing His-tagged SUMO-1 or SUMO-2 and parental cells were lysed in denaturing conditions to protect SUMO conjugation from the action of SUMO-deconjugating enzymes and lysates were subjected to enrichment of SUMOylated proteins on nickel-nitrilotriacetic acid (Ni-NTA) columns. Eluates were immunoblotted with α-TRAF3 or α-MYC tag antibody to confirm expression of Ubc9 and anti-TRAF3 to detect the levels of immunoprecipitated endogenous TRAF3. CV, control vector. (B) Knock-down of Ubc9 diminishes TRAF3 SUMOylation. HEK 293 cells were transfected with Ubc9 siRNA or an unrelated siRNA targeting luciferase (Luc) prior to lysis. Anti-TRAF3 immunoprecipitates were then immunoblotted with either anti-SUMO-1 or anti-SUMO-2 antibodies, as indicated. Results are representative of at least 4 independent experiments for (A) and (B).

doi:10.1371/journal.pone.0080470.g004
carcinoma cells were immunoprecipitated with anti-TRAF3 and precipitates were immunoblotted with anti-SUMO-1 antibody. Using normal lysis conditions we were unable to detect TRAF3-SUMO-1 conjugates (Fig. 3B, lanes 2, 4 and 6). As SUMOylation is readily reversible, we included the cysteine peptidase inhibitor iodoacetamide (IDO) in the lysis buffer which inhibits SUMO-deconjugating enzymes thus facilitating detection of SUMOylated proteins. Addition of IDO allowed detection of higher molecular weight bands representing SUMO-1-modified TRAF3 (Fig. 3B, lanes 1, 3 and 5). Similar results were obtained by analyzing lysates from mouse splenocytes, suggesting that SUMO-1 modification of TRAF3 is not a phenomenon restricted to transformed cells (Fig. 3C). TRAF3 was also found to be substrate for SUMO-2/3 in EJ cells (Fig. 3D).

To validate the link between Ubc9 and TRAF3 SUMOylation, we targeted Ubc9 in HEK 293 cells by either over-expressing a ‘dominant negative’ mutant or by RNA interference (RNAi). The mutated Ubc9 used in these experiments, Ubc9C93A, carries a substitution of Cys93 with Ala in the active site of the enzyme which renders it unable to catalyze formation of SUMO conjugates [22]. Endogenous TRAF3 was immunoprecipitated from cell lysates using an anti-TRAF3 polyclonal antibody and immunoblotted with anti-SUMO-1 or anti-SUMO-2/3 antibodies. As shown in Figure 4A, immunoreactive bands corresponding to TRAF3-SUMO conjugates were detected in control-transfected HEK 293 cell immunoprecipitates but their intensity was reduced in the presence of dominant negative Ubc9. Similarly, the RNAi-mediated knock-down of Ubc9 in EJ cells also led to significant reduction in the levels of SUMOylated TRAF3 (Fig. 4B). These data underscore the functional significance of the TRAF3:Ubc9 interaction in the SUMO modification of TRAF3.

Ubc9 is required for efficient TRAF3 degradation following CD40 receptor occupancy

TRAF3 directly interacts with and participates in CD40 signaling. In particular, CD40 activation in B cells results in cIAP-mediated ubiquitination and degradation of TRAF3 [26,27] which is required for NIK stabilization and non-canonical NF-κB2 signal activation [16,17]. We have examined the impact of Ubc9 ablation on CD40-mediated TRAF3 degradation in EJ cells, a cell line that was fundamental in the discovery of CD40 [28] and functionally responds to CD40 receptor occupancy [29]. As shown in Figure 5A, EJ cells transfected with control siRNA showed progressive loss of TRAF3 upon CD40 stimulation whereas the knock-down of endogenous Ubc9 attenuated this effect. As control, the levels of cIAP2, a known CD40 ligand (CD154)-inducible gene [30,31] did not differ between control and Ubc9 siRNA-transfected cells stimulated with recombinant CD154 (Fig. 5A).

Previous work has demonstrated that the TRAF3 gene encodes different isoforms [32]. The identity of the two immunoreactive bands detected by the anti-TRAF3 polyclonal antibody in Figure 5A was verified by RNAi. It was found that transfection of EJ cells with TRAF3 siRNAs diminished the expression of the higher molecular weight protein whereas siRNA targeting the RIP1 kinase or an unrelated siRNA targeting luciferase had no effect (Fig. 5B). In agreement with the established link between TRAF3 and non-canonical NF-κB signaling [16,17], the attenuated levels of

Figure 5. SUMOylation affects TRAF3 degradation and non-canonical NF-κB2 signaling in CD40-stimulated cells. (A) Knock-down of Ubc9 diminishes CD40 ligand (CD154) induced TRAF3 degradation. EJ cells were transfected with Ubc9 siRNA or an unrelated siRNA targeting luciferase (Luc) prior to stimulation with 0.5 μg/ml recombinant CD154 and lysis. Lysates were immunoblotted with anti-TRAF3, anti-cIAP2 or anti-β-actin antibodies. Results are representative of at least 5 independent experiments. (B) Validation of siRNA targeting TRAF3. EJ bladder carcinoma cells were transfected with siRNAs against TRAF3, RIP1 or the unrelated luciferase and knock-down efficacy and specificity were determined by immunoblotting cell lysates with anti-TRAF3, RIP1 or β-actin antibodies. (C) Lysates from Ubc9 knocked-down cells were immunoblotted with anti-NF-κB2 mAb recognizing both the full-length p100 and processed p52 form of NF-κB2 or with β-actin as loading control. Results are representative of 3 independent experiments. (D) Nuclear and cytoplasmic protein extracts were prepared from control and Ubc9 siRNA-transfected EJ cells before and after stimulation with 0.5 μg/ml CD40L and analyzed for p65/RelA expression by immunoblot. The transcription factor Sp1 was used as a marker for the purity of the nuclei cell extract preparation. Results are representative of 3 independent experiments.

doi:10.1371/journal.pone.0080470.g005
A. GST-CD40

GST-pulldown
I.B: α-TRAF3

Untreated
IDO

GST-CD40: CT CTA

64kD

I.B: α-TRAF3
(WCL)

64kD

GST-pulldown

Untreated
IDO

GST-CD40: CT CTA

Coomassie
Staining

B. GST-CD40CT

GST-CD40CTA

GST-pulldown

I.B: α-TRAF3

CV Ubc9C93A
CV Ubc9C93A

I.B: α-TRAF3
(WCL)

64kD

I.B: α-Myc tag
(WCL)

19kD

Discussion

TRAF3 is increasingly recognized as a key mediator of inflammatory and oncogenic signal transduction. The pleiotropic functions of TRAF3 largely depend on its ubiquitination status with K63-mediated Ub linkages regulating the activation of IRF3 and the IFN response and degradative K48-mediated ubiquitination being required for CD40-induced non-canonical NF-kB2 signaling [20]. Results presented in this study demonstrate that TRAF3 is subject to an additional post-translational modification, SUMOylation, through its direct interaction with the SUMO conjugating enzyme Ubc9. In particular, we have found TRAF3 to be modified by both SUMO-1 and SUMO-2/3. SUMO-2/3 can be conjugated to target proteins in a chain-wise fashion due to internal SUMO conjugation motifs, whereas SUMO-1 lacks this ability and often acts as a chain terminator [33,34]. It is thus likely that TRAF3 is modified by mixed SUMO-2/3 and SUMO-1 proteins with SUMO-1 “capping” and terminating SUMO-2/3 chains. The possibility that mono-SUMOylation also occurs requires evaluation particularly as TRAF3 contains numerous Lys residues which may serve as targets for SUMO modification.

A crosstalk between SUMOylation and ubiquitination has recently been suggested on the basis of co-purification of SUMO2/3 and ubiquitin conjugates and the accumulation of SUMO2/3 conjugates in cells treated with the proteasomal inhibitor MG132 [34,35,36,37]. Whilst clear evidence that SUMO and ubiquitin are linked to one another in the same chain has still to be determined, the reported findings show that SUMO2/3-modified proteins may be ubiquitinated and targeted for proteasomal degradation [35]. Indeed, once poly-SUMOylated, the promyelocytic leukemia (PML) protein recruits the ubiquitin ligase RING finger protein 4 (RFN4) [38,39] which elongates the SUMO chains by adding ubiquitin moieties to them. This, in turn, results in proteasomal degradation of PML [39]. SUMOylation has also been reported to positively modulate ubiquitination of the Williams-Beuren syndrome protein GTF2IRD1 [40]. Data shown in the present study provide additional support for the association between these post-translational modifications by demonstrating that Ubc9 knockdown significantly reduces CD40-mediated TRAF3 degradation and NF-kB2 processing. Despite the established role of ubiquitination in TRAF3 signal transduction [20,41], the Lys residues targeted for ubiquitin conjugation remain unknown and further studies are required to elucidate whether TRAF3 SUMOylation

SUMOylation increases the CD40-interacting capacity of TRAF3

SUMOylation may influence the ability of a modified substrate to interact with partner proteins. Given that CD40 ligation does not effectively induce TRAF3 degradation following Ubc9 knockdown, we surmised that TRAF3 SUMOylation may affect the interaction of TRAF3 with CD40. To address this hypothesis, the CD40 cytoplasmic tail (CT; Fig. 6A) was produced as fusion with GST in bacteria and incubated with lysates from HEK293 cells in the presence or absence of iodoacetamide (see Fig. 3B). GST pull-downs demonstrated that CD40 strongly interacts with TRAF3 in the absence of Ubc9 but association is reduced in the absence of SUMO protease inhibitor (Fig. 6A). As control, CD40 carrying a Thr254Ala mutation (CTA) known to abolish interactions with TRAF3 [3] failed to bind TRAF3 irrespective of IDO treatment.

To further validate this finding, a “dominant-negative” Ubc9C93A was over-expressed in HEK293 cells and lysates were incubated, in the presence of IDO, with GST-CD40CT or GST-CD40CTA bound to glutathione sepharose beads. Interacting proteins were fractionated by SDS-PAGE and immunoblotted with anti-TRAF3. Compared to vector-transfected cultures, Ubc9C93A reduced binding of TRAF3 to CD40.

Figure 6. TRAF3 SUMOylation affects its CD40-interacting capacity. (A) The binding of TRAF3 to GST-CD40CT increases when SUMO modification is maintained. HEK293 cells were lysed in the presence or absence of iodoacetamide (IDO) and lysates were incubated with bacterially produced GST-CD40CTA, carrying a Thr254Ala mutation (GST-CD40CTA) which abolishes interaction with TRAF3, bound to glutathione sepharose beads. Interacting proteins were fractionated by SDS-PAGE and immunoblotted (I.B) with anti-TRAF3 Ab. Whole cell lysates (WCL; 30 μg) were analyzed by immunoblot for TRAF3 expression levels. Lower right panel: Coomassie-stained gel showing GST-CD40CT and GST-CD40CTA produced in bacteria. (B) Over-expression of “dominant-negative” Ubc9C93A reduces binding of TRAF3 to CD40. HEK293 cells were transfected with Ubc9C93A or control vector (CV) and lysates were obtained using an IDO-containing lysis buffer and incubated with GST-CD40CT or GST-CD40CTA bound to glutathione sepharose beads. Interacting proteins were fractionated by SDS-PAGE and immunoblotted (I.B) with anti-TRAF3. Whole cell lysates (WCL; 30 μg) were analyzed for TRAF3 and Ubc9C93A expression levels by immunoblotting using anti-TRAF3 and Myc tag Abs, respectively. Results in (A) & (B) are representative of 3 independent experiments.

TRAF3 in Ubc9-ablated EJ cells correlated with reduced p100 NF-kB2 processing upon CD40 stimulation (Fig. 5C). In contrast, activation of the canonical NF-kB pathway, as determined by the extent of nuclear translocation of the p65/RelA NF-kB subunit following CD40 activation was similar between Ubc9 and control siRNA-transfected cells (Fig. 5D).

SUMOylation increases the CD40-interacting capacity of TRAF3

SUMOylation may influence the ability of a modified substrate to interact with partner proteins. Given that CD40 ligation does
Post-Translational Modification of TRAF3 by SUMO

Supporting Information

Figure S1 Ubch9 regulates the basal levels of TRAF3. EJ and HEK293 cells were transfected with Ubch9 siRNA or an unrelated siRNA targeting luciferase (Luc). Lysates (20 μg) were immunoblotted with anti-Traf3, Ubch9 or β-actin antibodies, as indicated. Results are representative of 5 independent experiments. Semi-quantitation of TRAF3 expression was performed using Image J [http://rsbweb.nih.gov/ij/]. (TIF)

Acknowledgments

We would like to thank Drs R. Hay, Y. Mo and G. Mosialos for providing reagents and Mariona Iamonn for technical assistance.

Author Contributions

Conceived and designed the experiments: AGE. Performed the experiments: SM KG. Analyzed the data: SM KG TVS AGE. Contributed reagents/materials/analysis tools: TVS. Wrote the paper: TVS AGE.

References

1. Cheng G, Cleary AM, YZ, ZS, Hong DI, Lederman S, et al. (1995) Involvement of Ccnf1, a relative of Traf, in CD40 signaling. Science 267: 1494–1498.
2. Mosialos G, Birkenbach M, Yalamanchili R, VanArsdell D, Ware C, et al. (1995) The Epstein-Barr Virus Transforming Protein LMP1 engages signaling proteins for the Tumour Necessor Factor Receptor Family. Cell 60: 389–399.
3. Hu BM, O’Rouke K, Boguski MS, Duet VM. (1994) A novel RING finger protein interacts with the cytoplasmic domain of CD40. J Biol Chem 269: 30069–30072.
4. Efopoulos AG, Young LS (2001) AIM1 structure and signal transduction. Semi Cancer Biol 11: 435–444.
5. Arch RH, Thompson CB (1996) 44:1B and 44c are members of a tumor factor (TNF)-nerv growth factor receptor subfamily that bind TNF receptor-associated factors and activate nuclear factor kappaB. Mol Cell Biol 16: 550–565.
6. Akiba H, Nakano H, Nishinaka S, Shiino M, Kobata T, et al. (1998) CD27, a member of the tumor necrosis factor receptor superfamily, activates NF-kappaB and stress-activated protein kinase-c-Jun N-terminal kinase via Traf2, TRAF5, and NF-kappaB-inducing kinase. J Biol Chem 273: 13537–13540.
7. Anzuza S, Nakano H, Tsuchiya T, Horie R, Nagai M, et al. (1997) Tumor necrosis factor receptor-associated factor 5 (Traf) and Traf2 are involved in CD30-mediated NF-kappaB activation. J Biol Chem 272: 2042–2045.
8. Hacker H, Redeki V, Blagov B, Kratchanovai I, Hua LC, et al. (2006) Specificity in Toll-like receptor signaling through distinct effector functions of TRAF3 and TRAF6. Nature 439: 204–207.
9. He JQ, Zarnegar B, Gagnegal G, Saha SK, Yamazaki S, et al. (2006) Rescue of TRAF3-null mice by p100 NF-kappaB B deficiency. J Exp Med 205: 2413–2418.
10. Perez de Diego R, Sancho-Shimizu V, Lorenzo I, Puel A, Plancoulaine S, et al. (2010) Human Traf3 adaptor molecule deficiency leads to impaired Toll-like receptor 3 response and susceptibility to herpes simplex encephalitis. Immunity 33: 400–411.
11. Sancho-Shimizu V, Perez de Diego R, Lorenzo I, Halwani R, Alangari A, et al. (2011) Herpes simplex encephalitis in children with autosomal recessive and dominant TRIF deficiency. J Clin Invest 121: 4899–4902.
12. Keats JJ, Fonseca R, Chesi M, Schop R, Baker A, et al. (2007) Promiscuous mutations activate the noncanonical NF-kappaB pathway in multiple myeloma. Cancer Cell 12: 115–130.
13. Anumuzzia CM, Davis RE, Demchenko Y, Bellamy W, Gahrea A, et al. (2007) Frequent engagement of the classical and alternative NF-kappaB pathways by diverse genetic abnormalities in multiple myeloma. Cancer Cell 12: 115–130.
14. Efopoulos AG, Dawson CW, Mosialos G, Foetmann JE, Rowe M, et al. (1999) CD40-induced growth inhibition in epithelial cells is mimicked by Epstein-Barr virus-encoded LMP1: involvement of TRAF3 as a common mediator. J Biol Chem 274: 22924–22929.
15. VanArsdell TL, VanArsdell SL, Force WR, Walter TN, Mosialos G, et al. (1997) Lymphotoxin-beta receptor signaling complex: role of tumor necrosis factor receptor-associated factor 3 recruitment in cell death and activation of nuclear factor kappaB. Proc Natl Acad Sci U S A 94: 2460–2465.
16. Gandem S, Siervo F, Basten A, Mackay F, Brink R (2008) TRAF2 and TRAF3 signal adapters act cooperatively to control the maturation and survival signals delivered to B cells by the BAFF receptor. Immunity 28: 391–401.
17. Liao G, Zhang M, Harbaj EW, Sun SC (2004) Regulation of the NF-kappaB-inducing kinase by tumor necrosis factor receptor-associated factor 3-induced degradation. J Biol Chem 279: 26243–26250.
18. Perez de Diego R, Sancho-Shimizu V, Lorenzo I, Puel A, Plancoulaine S, et al. (2010) Human Traf3 adaptor molecule deficiency leads to impaired Toll-like receptor 3 response and susceptibility to herpes simplex encephalitis. Immunity 33: 400–411.
19. Coope HJ, Atkinson PG, Hulse B, Belich M, Jauzen J, et al. (2002) CD40 regulates the processing of NF-kappaB p105 to p52. Embry 21: 5373–5383.
20. Valuhaquistarpus S, Matsuowada A, Zhang W, Tseng PH, Keats J, et al. (2008) Nonredundant and complementary functions of TRAF2 and TRAF5 in a ubiquitination cascade that activates NIK-dependent alternative NF-kappaB signaling. Nat Immunol 9: 1364–1370.
21. Tshah MH, Rodriguez MS, Xiaolindas DP, Hay RT (2009) Detection of protein SUMOylation in vivo. Nat Protoc 4: 1363–1371.
22. Zha S, Sachdeva M, Wu F, Lu Z, Mo YY (2010) Ubch9 promotes breast cell invasion and metastasis in a sumoylation-independent manner. Oncogene 29: 1763–1772.
23. Davies CC, Mak TW, Young LS, Efopoulos AG (2005) TRAF3 is required for TRAF2-dependent CD40 signal transduction in nonhemopoietic cells. Mol Cell Biol 25: 9806–9819.
24. Gyuris J, Golemis E, Chertkow H, Brent R (1993) Gdi1, a human G1 and S phase protein phosphatase that associates with Cdk2. Cell 75: 791–803.
25. Lin X, Liang M, Liang YY, Brunicardi FC, Feng XH (2003) SUMO-1/Ubch9 promotes nuclear accumulation and metabolic stability of tumor suppressor Smad4. J Biol Chem 278: 31014–31040.
26. Hostager BS, Haxhiahsot A, Rowland sL, Bishop GA (2005) Tumor necrosis factor receptor-associated factor 2 (TRAF2)-deficient B lymphocytes reveal novel roles for TRAF2 in CD40 signaling. J Biol Chem 270: 45302–45309.
27. Brown KD, Hostager BS, Bishop GA (2001) Differential signaling and tumor necrosis factor receptor-associated factor (TRAF) degradation mediated by CD40 and the Epstein-Barr virus oncoprotein latent membrane protein 1 (LMP1). J Exp Med 193: 943–954.
28. Nunnenkone I, Clark EA, Seed B (1989) A B-lymphocyte activation molecule related to the nerve growth factor receptor and induced by cytokines in carcinomas. Embryo J 8: 1403–1410.
29. Knox PG, Davies GC, Ioannou M, Efopoulos AG (2011) The death domain kinase RIP1 links the immunoregulatory CD40 receptor to apoptotic signaling in carcinomas. J Cell Biol 192: 391–399.
30. Hong SY, Yuan WH, Park JH, Kang SG, Ahn JH, et al. (2000) Involvement of two NF-kappaB B binding elements in tumor necrosis factor alpha -,-. CD40- and Epstein-Barr virus latent membrane protein 1-mediated induction of the cellular inhibitor of apoptosis protein 2 gene. J Biol Chem 275: 18022–18028.
31. Stewart R, Wei W, Challa A, Armitage RJ, Arrand J, et al. (2007) CD14 tone sets the signalling pathways and transcription generated in model CD40-phosphorcompent L3055 Burkitt’s lymphoma cells. J Immunol 179: 2705–2712.
32. van Eyndhoven WG, Frank D, Kalachnikov S, Cleary AM, Hong DH, et al. (1998) A single gene for human TRAF-3 at chromosome 14q32.3 encodes a variety of mRNAs species by alternative polyadenylation, mRNA splicing and transcription initiation. Mol Immunol 35: 1189–1206.
33. Muller S, Hoeg C, Prywolak S, Jentusch S (2001) SUMO, ubiquitin’s mysterious cousin. Nat Rev Mol Cell Biol 2: 202–210.
34. Ulrich HD (2008) The fast-growing business of SUMO chains. Mol Cell 32: 301–305.
35. Schimmel J, Larsen KM, Matir I, van Hagen M, Cox J, et al. (2008) The ubiquitin-proteasome system is a key component of the SUMO-2/3 cycle. Mol Cell Proteomics 7: 2107–2122.
36. Geoffroy MC, Hay RT (2009) An additional role for SUMO in ubiquitin-mediated proteolysis. Nat Rev Mol Cell Biol 10: 564–568.
37. Praefcke GJ, Hofmann K, Dohmen RJ (2012) SUMO playing tag with ubiquitin. Trends Biochem Sci 37: 23–31.
38. Lallemand-Breitenbach V, Jeanne M, Benhenda S, Naar R, Lei M, et al. (2008) Arsenic degrades PML or PML-RARalpha through a SUMO-triggered RNF4/ubiquitin-mediated pathway. Nat Cell Biol 10: 547–555.
39. Tatham MH, Geoffroy MC, Shen L, Plechanovova A, Hattersley N, et al. (2008) RNF4 is a poly-SUMO-specific E3 ubiquitin ligase required for arsenic-induced PML degradation. Nat Cell Biol 10: 538–546.
40. Widagdo J, Taylor KM, Gunning PW, Hardeman EC, Palmer SJ (2012) SUMOylation of GTF2IRD1 regulates protein partner interactions and ubiquitin-mediated degradation. PLoS One 7: e49203.
41. Matsuzawa A, Tseng PH, Vallabhapurapu S, Luo JL, Zhang W, et al. (2008) Essential cytoplasmic translocation of a cytokine receptor-assembled signaling complex. Science 321: 663–668.
42. Loskog AS, Eliopoulos AG (2009) The Janus faces of CD40 in cancer. Semin Immunol. 21(5):301–7.